No Evidence for JAK2V617F Mutation in Monoclonal B Cells in 2 Patients with Polycythaemia Vera and Concurrent Monoclonal B Cell Disorder
Authors:
- C. StijnisCSC. Stijnis
- W.G.M. KroesWKW.G.M. Kroes
- S. BalkassmiSBS. Balkassmi
- E.W.A. MarijtEME.W.A. Marijt
- A.P. van RossumARA.P. van Rossum
- E. BakkerEBE. Bakker
- L.T. VlasveldLVL.T. Vlasveld
- 10 August 2012
- journal article
- case report
- Published by S. Karger AG in Acta Haematologica
- Vol. 128 (3) , 183-186
Abstract
Occurrence of Philadelphia chromosome-negative myeloproliferative neoplasms (Ph– MPN) and lymphoproliferative disorders, like B cell chronic lymphocytic leukaemia (B-CLL), in the same patient is rare. JAK2V617F mutation was recently introduced as a powerful diagnostic tool for Ph– MPN. JAK2V617F mutation is not present in B-CLL. In 4 previously reported patients with JAK2V617F-positive Ph– MPN and B-CLL there was no definitive proof of JAK2V617F mutation in B-CLL cells, although this was suggested in 1 patient. We present 2 patients with JAK2V617F-positive polycythaemia vera who subsequently developed a monoclonal B cell disorder. The granulocytes were separated from the mononuclear cells by centrifugation on density gradient. Using an ARIA-SORP sorter, the CD20+/CD5+ B cells were separated from the CD20+/CD5– B cells, T cells, NK cells and monocytes. On each of the fractions JAK2V617F mutation was analysed by allele-specific competitive blocker-PCR. In both patients JAK2V617F mutation was present in granulocytes confirming the clinical diagnosis of polycythaemia vera. We did not detect the JAK2V617F mutation in the CD20+/CD5+ B cells but detected it in CD20+/CD5– B cells, T and NK cells, indicating a lymphoid subdifferentiation of the JAK2V617F MPN clonality. JAK2V617F MPN and monoclonal B cell disorder can coexist but there is no evidence that the proliferative behaviour of these B cells is mediated through the JAK2V617F mutation.Keywords
This publication has 16 references indexed in Scilit:
- Self-Renewing Hematopoietic Stem Cell Is the Primary Target in Pathogenesis of Human Chronic Lymphocytic LeukemiaCancer Cell, 2011
- The JAK2 V617F mutation involves B‐ and T‐lymphocyte lineages in a subgroup of patients with Philadelphia‐chromosome negative chronic myeloproliferative disordersBritish Journal of Haematology, 2007
- B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosisHaematologica, 2007
- The Myeloproliferative DisordersNew England Journal of Medicine, 2006
- Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosisBlood, 2006
- The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiationProceedings of the National Academy of Sciences, 2006
- JAK2 V617F mutation is absent in chronic lymphocytic leukemiaLeukemia & Lymphoma, 2006
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersThe Lancet, 2005
- The association of erythrocytosis and chronic lymphocytic leukemiaCancer, 1992
- Evidence for the involvement of B lymphoid cells in polycythemia vera and essential thrombocythemia.Journal of Clinical Investigation, 1985